Recent Updates
Recently added Catalysts

Primatene Mist HFA

Phase 2

Asthma | Small molecule | Respiratory |Amphastar Pharmaceuticals, Inc.|Last Updated: Mar 17, 2016

Target and mechanism

ModalitySmall molecule

Also known as Arm T1: Primatene Mist HFA, Arm T2: Primatene Mist HFA

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment24

FDA Designations

No designations recorded

Clinical trial landscape

Primatene Mist HFA · 1 trial · 1 indication

Phase 2 1
NCT01255709Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICSAsthma
COMPLETED24 Analytics
PHASE2COMPLETED
Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS
AsthmaUnlock trial analytics

Study Endpoints

Primary Endpoints

Pharmacokinetics including maximum concentration and area under the curve
-30, 2, 5, 7.5, 10, 12.5, 15, 20, 25, 30, 45, 60, 90, 120, 240 and 360 min postdose.

Samples will be analyzed with an established LC/MS/MS method, with a quantitative detection limit of 0.02 ng/mL, for both epinephrine-d3 and epinephrine-h3. * Mean Maximum concentration of epinephrine (Cmax for epinephrine) * Mean Area Under the Curve (AUC) for epinephrine * Time to maximum concentration (tmax) and Half life of the drug (t1/2) * Epinephrine concentrations versus time

Secondary Endpoints

Vital Signs
within 30 min predose, at 30, 60 and 360 min postdose
12-lead Electrocardiogram (ECG)
within 30 min pre-dose, and at 15 and 120 min post-dose
Telemetry ECG
within 30 min pre-dose, and during the initial 5 min post-dose
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelCROSSOVER
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Arm T1 Primatene Mist HFAEXPERIMENTALepinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes
Arm C Primatene MistACTIVE_COMPARATORepinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes
Arm T2 Primatene Mist HFAEXPERIMENTALepinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes

Interventions

NameTypeDescription
Arm T1: Primatene Mist HFADRUGepinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes
Arm T2: Primatene Mist HFADRUGepinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes
Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)DRUGepinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 30 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Generally healthy at screening; * Body weight ≥ 50 kg for men and ≥ 45 kg for women; * Sitting blood pressure ≤ 135/90 mmHg; * Demonstrating negative hIV, HBsAG and DCV-Ab screen tests; * Women of child-bearing potential must be non-pregnant, non-lactating, and practicing a cl...

Countries:United States
Unlock Eligibility Criteria